Show simple item record

dc.contributor.authorMateo Marin, María Antonia 
dc.contributor.authorAlves Bezerra, Michele 
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.date.accessioned2025-03-28T08:43:19Z
dc.date.available2025-03-28T08:43:19Z
dc.date.issued2024
dc.identifier.issn1539-7262
dc.identifier.issn0022-2275
dc.identifier.urihttp://hdl.handle.net/10498/36002
dc.description.abstractHepatic accumulation of triglycerides is a hallmark feature of metabolic dysfunction-associated steatotic liver disease (MASLD). Growing evidence indicates that increased rates of de novo lipogenesis (DNL) are one of the earliest metabolic changes promoting hepatic steatosis in the onset of MASLD. The first step in DNL is catalyzed by acetyl-CoA carboxylases (ACC), which mediate the conversion of acetyl-CoA into malonyl-CoA. Given the critical role of ACC enzymes on DNL, ACC-based therapies have emerged as an attractive approach to address MASLD, leading to the development of pharmacologic inhibitors of ACC. In clinical trials, several of those compounds led to decreased DNL rates and improved hepatic steatosis in patients with MASLD. In this review, we describe the development of ACC dual inhibitors and isoform-specific inhibitors along with their clinical testing using monotherapy and combination therapy approaches. We also discuss their efficacy and safety profiles, identifying potential directions for future research. It is anticipated that advances in ACC-based therapies will be critical to the management of MASLD.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherAmerican Society for Biochemistry and Molecular Biology Inc.es_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceJournal of Lipid Researches_ES
dc.subjectACC inhibitorses_ES
dc.subjectde novo lipogenesises_ES
dc.subjectDNLes_ES
dc.subjectDNL inhibitorses_ES
dc.subjecthepatic steatosises_ES
dc.subjectlipid metabolismes_ES
dc.subjectMASLDes_ES
dc.titleTargeting acetyl-CoA carboxylases for the treatment of MASLDes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1016/J.JLR.2024.100676
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional